Efficacy of OROS Methylphenidate for the Treatment of ADHD.
- Author:
Jungeun SONG
1
;
Bongseog KIM
;
Jung Woo SON
;
Hanik K YOO
;
Soyoung Irene LEE
;
Doug Hyun HAN
;
Dong Ho SONG
Author Information
1. Department of Psychiatry, Kwandong University College of Medicine, Myongji Hospital, Goyang, Korea.
- Publication Type:Original Article ; Clinical Trial
- Keywords:
Attention-Deficit/Hyperactivity Disorder;
OROS methylphenidate;
Efficacy
- MeSH:
Achievement;
Humans;
Methylphenidate;
Phenazines;
Quality of Life
- From:Journal of the Korean Academy of Child and Adolescent Psychiatry
2012;23(Suppl):S12-S23
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Attention-deficit/hyperactivity disorder (ADHD) is one of the common psychiatric problems in childhood. The symptoms of ADHD tend to last for adulthood and the patients suffer from various comorbid problems and functional impairments. Methylphenidate (MPH) is the first choice of pharmacotherapy for ADHD and many researches have demonstrated its efficacy. We reviewed the clinical trials for efficacy of MPH focusing on Osmotic-Controlled Release Oral delivery System Methylphenidate (OROS MPH). It was identified that MPH improved core symptom of ADHD, peer relationship and health related quality of life and might improve various aspects of cognitive function. It was proved that the efficacy of OROS MPH was better than placebo and comparable to immediate release MPH (IR MPH) dosed three times daily in various studies. Especially, parent's preference of OROS MPH was better than IR MPH. The efficacy of MPH for academic achievement was equivocal. Long-term efficacy of OROS MPH was also inconclusive and further study is necessary.
